MET variant as a prognostic marker in clear cell renal cell carcinoma

Share :
Published: 31 Jan 2014
Views: 4165
Rating:
Save
Dr Ari Hakimi - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Ari Hakimi of the Memorial Sloan-Kettering Cancer Center, New York, USA, at the ASCO GU congress 2014 discusses the MET variant as a prognostic marker in clear cell renal cell carcinoma (ccRCC) and its future implications.